MediPharm Labs(DE:MLZ)
€0.040.00 (0.00%)
DE:MLZ
MediPharm Labs earnings date
€0.04
At close:0.00 (0.00%)
MediPharm Labs (MLZ) Q3 2026 Earnings Report
1 Followers
DE:MLZ Q3 2026 EPS Results
- Actual EPS
- EUR 0.00
- Consensus EPS
- EUR 0.00
- Beat/Miss
- Beat by +EUR 0.00
- One Year Ago EPS
- -EUR 0.01
DE:MLZ Q3 2026 Revenue Results
- Actual Revenue
- EUR 7.50M
- Expected Revenue
- EUR 6.47M
- Beat/Miss
- Beat by +EUR 1.03M
- YoY Revenue Growth
- +3.09%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
DE:MLZ Upcoming Earnings
MediPharm Labs's next earnings date is estimated for March 31, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
DE:MLZ Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive. MediPharm reported 18% sequential revenue growth, strong international medical performance, positive net income for the second consecutive quarter, positive adjusted EBITDA for the third consecutive quarter, lower operating expenses and a strong balance sheet. These achievements outweighed the stated challenges in Australia, the impact of Veterans Affairs Canada reimbursement changes, the year-to-date revenue decline versus the prior year and the sequential gross margin decrease.
Company Guidance
Management said Australia’s recovery will take time, but the actions taken are believed to better align the portfolio with evolving patient demand and position the business for improved performance over time. The Q1 restructuring initiatives are expected to generate more than $1 million in annualized savings. MediPharm intends to continue expanding in regulated medical markets, pursue future commercialization of its metered dose inhaler in the U.K. and European Union, and evaluate selective M&A opportunities that meet its return thresholds. Brazil remains an attractive longer-term growth opportunity, while the LiBBY study may lead to potential additional clinical development or regulatory pathways and/or strategic partnerships.
- Disciplined M&A StrategyMediPharm continues to evaluate selective M&A opportunities focused on regulated medical markets, capabilities, market access and the quality and sustainability of earnings. Since the VIVO transaction, the company has evaluated multiple opportunities while maintaining discipline on valuation, strategic fit, integration risk and capital use.
- Strong Q3 Revenue GrowthNet revenue was $11.8 million, increasing 18% sequentially from Q2, largely driven by the German and U.K. businesses, which grew 19% and 220%, respectively.
- Continued Profitability and Positive EBITDAMediPharm achieved positive net income for the second consecutive quarter and positive adjusted EBITDA of $0.4 million for the third consecutive quarter. Year to date, the company generated $1.4 million of positive adjusted EBITDA.
- International Medical GrowthInternational medical cannabis revenue was $6.9 million, representing approximately 59% of total quarterly revenue and growing 20% sequentially from Q2.
- Germany Delivered Strong GrowthGerman revenue increased 19% sequentially and 81% year over year to $5 million, supported by demand across flower, oil and dronabinol and continued expansion of the Beacon and Wildlife branded portfolios.
- U.K. Business ExpansionThe U.K. business grew 220% sequentially in Q3, and MediPharm expanded its business with established partners.
- Improved Gross Profit and MarginGross profit was $3.8 million, representing a 32% gross margin and a 27% increase versus the prior year. Management attributed gross margin performance to disciplined product mix management, branded international sales and continued cost control.
- Operating Expense ReductionTotal operating expenses were $3.6 million, declining 25% year over year and 11% sequentially. The company said its Q1 restructuring initiatives are expected to generate more than $1 million in annualized savings.
- Strong Balance Sheet and LiquidityMediPharm ended the quarter with over $10 million in cash, virtually no debt and ownership of two GMP production facilities with a combined appraised value in excess of $15 million. The company also remained current on excise taxes, sales taxes and trade payables.
- Cash-Generating CapabilityThe cash position remained materially unchanged over the past 12 months while the company generated approximately $1 million of operating cash flow before working capital.
- Regulated Medical PlatformMore than 80% of revenue is generated through prescription-based medical channels. The platform includes a Health Canada drug establishment license, multiple EU GMP certifications, ANVISA GMP certification from Brazil, capabilities supporting Australia, an FDA-registered facility with experience supplying pharmaceutical-grade cannabinoids into the United States, and Canadian natural health product licenses and registrations.
- Expansion Across International Medical MarketsMediPharm continued supplying GMP medical cannabis oil in France and advanced regulatory dossiers with its local partner, launched products through national pharmacy channels in Brazil, continued building Beacon Medical in New Zealand and expanded its business with established partners in the U.K.
- Brazil Commercial LaunchMediPharm launched its full-spectrum CBD oral oil, developed and manufactured at its Barrie facility, through pharmaceutical partner Alko do Brasil. Brazil was described as an attractive long-term medical cannabis opportunity aligned with the company's pharmaceutical manufacturing and regulatory capabilities.
- Metered Dose Inhaler Regulatory ProgressThe company received a notified body opinion supporting the pathway toward future commercialization of its metered dose inhaler in the U.K. and European Union. Shortly after quarter end, MediPharm entered Panama with its first commercial shipment of CBD metered dose inhalers.
- Stable Canadian Medical RevenueCanadian medical cannabis revenue was $2.3 million in Q3, consistent with Q2 and reflecting stabilization following the Veterans Affairs Canada reimbursement reduction in Q2.
- Growth in Veteran Patient Base and PartnershipsHarvest Medicine reached a new high in active veteran patients during the quarter, while third-party medical partnerships continued to expand the availability of MediPharm products beyond its own platform.
- Premium Oil Market PositionMediPharm continued to defend its #2 leadership position in premium oils. The company launched Pocket Drops in Ontario and Alberta, which gained encouraging early traction and helped support oil market share despite contraction in the overall category.
- Pharma and B2B Revenue GrowthPharma and B2B revenue increased to $1.2 million in Q3, reflecting higher volumes from existing customers and new business wins. The company continues to pursue contract manufacturing and longer-term cannabinoid-based pharmaceutical development opportunities.
- LiBBY Clinical Trial ResultsThe Phase II randomized, double-blind, placebo-controlled LiBBY study evaluated MediPharm's proprietary cannabinoid formulation for agitation in patients with advanced dementia. The company stated that the product met its primary and secondary endpoints and produced statistically significant improvement for patients on the product. MediPharm filed two U.S. provisional patents on the formulation.
DE:MLZ Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 31, 2027 | 2026 (Q4) | ―- | 0 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.000.00 | -0.01 | 100.00% (+0.01) | |
| Aug 13, 2026 | 2026 (Q2) | -0.000.00 | -0.01 | 100.00% (+0.01) | |
| May 13, 2026 | 2026 (Q1) | -0.000.00 | 0 | ― | |
| Mar 30, 2026 | 2025 (Q4) | -0.000.00 | 0 | 100.00% (+0.00) | |
| Nov 13, 2025 | 2025 (Q3) | -0.00-0.01 | 0 | -42.86% (-0.00) | |
| Aug 14, 2025 | 2025 (Q2) | -0.00-0.01 | -0.01 | 0.00% (+0.00) | |
| May 14, 2025 | 2025 (Q1) | ―- | -0.01 | ― | |
| Mar 31, 2025 | 2024 (Q4) | -0.000.00 | -0.01 | 100.00% (+0.01) | |
| Nov 14, 2024 | 2024 (Q3) | -0.00-0.00 | -0.01 | 30.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
